about
A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: a dual center retrospective analysis.Aging biology and novel targets for drug discovery.Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment.T-cell and B-cell signaling biomarkers and treatment targets in lupus.Pathogenesis and management of graft-versus-host disease.Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradationThe efficacy of sirolimus in the treatment of patients with refractory uveitisSirolimus for GVHD prophylaxis in allogeneic stem cell transplantation.Sirolimus: its role in nephrology.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.Sirolimus impairs gonadal function in heart transplant recipients.The effects of topical aqueous sirolimus on tear production in normal dogs and dogs with refractory dry eye.Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys.New and emerging therapies for acute and chronic graft versus host disease.Rapamycin causes upregulation of autophagy and impairs islets function both in vitro and in vivo.Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium.Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation.
P2860
Q33387336-A52FD46A-88C0-4A99-906E-1DE4F5E39BDCQ33416874-93554F2A-092D-4E8B-AEB4-95B585CA1A1BQ33558234-76F24388-5BFD-4A6B-B30E-6A570DD0175BQ33608479-C13C045F-1DB1-4C77-9847-FBD43A149600Q33718893-479CFF95-40AC-418F-9E63-041CE02F56E9Q34077479-D066FC07-8786-48C6-9222-E933605DBCCEQ34939946-90C68762-A340-404A-AE63-3581B83E3682Q35593216-F68CEF3A-6D6F-49F5-BE7E-5C9A2429C5AFQ35845541-CA106B81-F52B-469A-9E32-BE3C7C0BE276Q36341793-9A53C38C-5257-4237-AC12-A72E69C8B0E3Q38202155-9A650657-757A-4960-AAE4-49E69B132B0EQ44935460-6ECFF038-29DD-4667-ADED-DB64E7293D48Q45069146-53C87683-C03D-4B03-896A-6BB2ADBD6323Q46702750-48C027DD-9E84-4167-9CB5-5DD8320D96FBQ49238507-59F1B207-F53E-421B-A51F-727B8D4E9A45Q50510804-A58041E6-C893-4CE7-A99E-6FE55DAF79FEQ51493366-42875376-A97D-438D-A081-56492D1C84A6Q53598748-A10162D6-BEF1-4B9D-970C-25AE7148D211
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Molecular actions of sirolimus: sirolimus and mTor.
@ast
Molecular actions of sirolimus: sirolimus and mTor.
@en
type
label
Molecular actions of sirolimus: sirolimus and mTor.
@ast
Molecular actions of sirolimus: sirolimus and mTor.
@en
prefLabel
Molecular actions of sirolimus: sirolimus and mTor.
@ast
Molecular actions of sirolimus: sirolimus and mTor.
@en
P1476
Molecular actions of sirolimus: sirolimus and mTor.
@en
P2093
P304
P356
10.1016/S0041-1345(03)00230-6
P407
P433
P577
2003-05-01T00:00:00Z